<?xml version="1.0" encoding="UTF-8"?>
<p>However, chloroquine/hydroxychloroquine has, so far, undoubtedly taken the lion's share (178 hits), and it has attracted a lot of media attention. In that respect, the results from an initial pan-European endeavor (“Discovery”), now conducted largely in France because of enrollment difficulties, are eagerly awaited. This drug has a “mixed” mode of action. Indeed, it acts as an anti-viral (presumably through inhibition of lysosomal enzymes requiring an acidic pH and of activation of endolysosomes, see above section “Mechanisms of entry”) and as an anti-inflammatory molecule, and it has notably been used in inflammatory rheumatic diseases (
 <xref rid="B89" ref-type="bibr">89</xref>). Despite a relative safe profile, having been administered to millions of people over the years, worries have nevertheless arisen about cardiac issues in many individuals with severe Covid-19, and this will have to be properly assessed (
 <xref rid="B90" ref-type="bibr">90</xref>).
</p>
